Abstract:Metal-based complexes have occupied a pioneering niche in the treatment of many chronic diseases, including various types of cancers. Despite the phenomenal success of cisplatin for the treatment of many solid malignancies, a limited number of metallo-drugs are in clinical use against cancer chemotherapy till date. While many other prominent platinum and non‑platinum- based metallo-drugs (e.g. NAMI-A, KP1019, carboplatin, oxaliplatin, titanocene dichloride, casiopeinas® etc) have entered clinical trials, many have failed at later stages of R&D due to deleterious toxic effects, intrinsic resistance and poor pharmacokinetic response and low therapeutic efficacy. Nonetheless, research in the area of medicinal inorganic chemistry has been increasing exponentially over the years, employing novel target based drug design strategies aimed at improving pharmacological outcomes and at the same time mitigating the side-effects of these drug entities. Over the last few decades, natural products became one of the key structural motifs in the anticancer drug development. Many eminent researchers in the area of medicinal chemistry are devoted to develop new 3d-transition metal-based anticancer drugs/repurpose the existing bioactive compounds derived from myriad pharmacophores such as coumarins, flavonoids, chromones, alkaloids etc. Metal complexes of natural alkaloids and their analogs such as luotonin A, jatrorrhizine, berberine, oxoaporphine, 8-oxychinoline etc. have gained prominence in the anticancer drug development process as the naturally occurring alkaloids can be anti-proliferative, induce apoptosis and exhibit inhibition of angiogenesis with better healing effect. While some of them are inhibitors of ERK signal-regulated kinases, others show activity based on cyclooxygenases-2 (COX-2) and telomerase inhibition. However, the targets of these alkaloid complexes are still unclear, though it is well-established that they demonstrate anticancer potency by interfering with multiple pathways of tumorigenesis and tumor progression both in vitro and in vivo. Over the last decade, many significant advances have been made towards the development of natural alkaloid-based metallo-drug therapeutics for intervention in cancer chemotherapy that have been summarized below and reviewed in this article.

Metal Complexes of Natural Product Like-compounds with Antitumor Activity.

Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity

Development of Natural Product-Conjugated Metal Complexes as Cancer Therapies

Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides-Current Developments in Structure-Activity Relationship

Anticancer Metallocenes and Metal Complexes of Transition Elements from Groups 4 to 7

Metal N-heterocyclic Carbene Complexes As Potential Metallodrugs in Antitumor Therapy

Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects

Metal-based Anticancer Chemotherapeutic Agents.

The Therapeutic Potential in Cancer of Terpyridine‐Based Metal Complexes Featuring Group 11 Elements

Recent Researches in Metal Supramolecular Complexes As Anticancer Agents.

Recently Reported Biological Activities and Action Targets of Pt(II)- and Cu(II)-Based Complexes

Metal-N-heterocyclic carbene complexes as anti-tumor agents

Review: Recent Advances and Future Development of Metal Complexes As Anticancer Agents

Research progress of natural product-conjugated platinum and gold complexes as potential antitumor agents

A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies

Trends of Platinum and Metal-Arene Anticancer Drugs Based on Natural Products

Transition metal complexes with tetradentate Schiff bases (N 2 O 2 ) obtained from salicylaldehyde: A review of their possible anticancer properties

Metal-coordinated nanodrugs based on natural products for cancer theranostics

Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics

Metal-based antitumor compounds: beyond cisplatin

Metallo-Drugs in Cancer Therapy: Past, Present and Future